1-3 of 3
Robert M Sharkey, Ph.D.
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A New Antibody-Drug Conjugate Composed of an Anti-HLA-DR IgG4 Antibody, IMMU-114, and SN-38, Is Active in Experimental Acute Myelocytic Leukemia (AML), Acute Lymphocytic Leukemia (ALL), and Multiple Myeloma (MM)

David M Goldenberg, ScD, MD, Robert M Sharkey, Ph.D., Serengulam V Govindan, PhD, Maria Zalath, BA, Ali Mostafa, BS, Thomas M Cardillo, Ph.D.
Journal: Blood
Blood (2016) 128 (22): 3958.
https://doi.org/10.1182/blood.V128.22.3958.3958
Published: 2016
Journal Articles

Epratuzumab (Humanized Anti-CD22 MAb) Conjugated with SN-38, a New Antibody-Drug Conjugate (ADC) for the Treatment of Hematologic Tumors: Preclinical Studies Alone and In Combination with Veltuzumab, a Humanized Anti-CD20 MAb

David M Goldenberg, Sc.D., M.D., Serengulam Govindan, Ph.D., Tom M Cardillo, Ph.D., Robert M Sharkey, Ph.D.
Journal: Blood
Blood (2010) 116 (21): 3941.
https://doi.org/10.1182/blood.V116.21.3941.3941
Published: 2010
Journal Articles

Radioimmunotherapy of Non-Hodgkin Lymphoma is Improved without Increasing Toxicity by Combination with Antibody immunotherapy.

Robert M Sharkey, Ph.D., M. Jules Mattes, Ph.D., Habibe Karacay, Ph.D., Chien-Hsing Chang, PhD, Edmund A Rossi, PhD, William J McBride, Ph.D., David M. Goldenberg, ScD, MD
Journal: Blood
Blood (2008) 112 (11): 1588.
https://doi.org/10.1182/blood.V112.11.1588.1588
Published: 2008